




CASE LD0268 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Anastasia P. Winslow

Type or print name



Signature

May 21, 2004

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

FRANCIS Y.F. LEE

APPLICATION NO: 10/091,061

FILED: MARCH 5, 2002

FOR: COMBINATION OF EPOTHILONE ANALOGS AND  
CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF  
PROLIFERATIVE DISEASES

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609 (252-6996)  
Date: May 21, 2004

  
Anastasia P. Winslow  
Attorney for Applicant  
Reg. No. 40,875



CASE LD0268 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Anastasia P. Winslow

Type or print name

Signature

May 21, 2004

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

FRANCIS Y.F. LEE

APPLICATION NO: 10/091,061

FILED: MARCH 5, 2002

FOR: COMBINATION OF EPOTHILONE ANALOGS AND  
CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF  
PROLIFERATIVE DISEASES

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


06/01/2004 SSANDARA 00000004 10091061

01 FC:1401 — 330.00 DA  
02 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6996



---

Anastasia P. Winslow  
Attorney for Applicant  
Reg. No. 40,875

Date: May 21, 2004

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
LD0268 NP  
APPLICATION NO.  
10/091,061  
APPLICANT  
Francis Y.F. Lee  
FILING DATE  
MARCH 5, 2002Group  
1614

## U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL		U.S. APPLICATION DOCUMENT	DATE OF PUBLICATION	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2002/0177548	11/28/02	Schwendner et al.			
	AB	2003/0191162	10/9/03	Langecker et al.			
	AC	2004/0023925	2/5/04	Chang et al.			

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AD	5,728,687	3/17/98	Bissery			
	AE	6,441,026	8/27/02	Bissery			
	AF	6,462,017	10/8/02	Rudolph et al.			
	AG	6,586,428	7/1/03	Geroni et al.			
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AJ	WO 00/38519	7/6/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 00/38730	7/6/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 01/07082	2/1/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 01/34133	5/17/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/49287	7/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AO	Bissery, M.C. et al., "Preclinical In Vivo Activity of Docetaxel-Containing Combinations", Proceedings of ASCO, Vol. 14, No. 1599, p. 489 (1995)
	AP	Bissery, M.-C. et al., "Preclinical Profile of Docetaxel (Taxotere): Efficacy as a Single Agent and in Combination", Seminars in Oncology, Vol. 22, No. 6, Suppl. 13, pp. 3-16 (1995)
	AQ	Holmes, F.A., "Paclitaxel Combination Therapy in the Treatment of Metastatic Breast Cancer", Seminars in Oncology, Vol. 23, No. 5, Suppl. 12, pp. 29-39 (1996)


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.  
LD0268 NP  
APPLICATION NO.  
10/091,061  
APPLICANT  
Francis Y.F. Lee  
FILING DATE  
MARCH 5, 2002

Group  
1614

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	2AA	WO 01/82949	11/8/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AB	WO 02/39958	5/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AC	WO 02/089824	11/14/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AD						<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
LD0268 NP  
APPLICATION NO.  
10/091,061  
APPLICANT  
Francis Y.F. Lee  
FILING DATE  
MARCH 5, 2002

Sheet 3 of 3

Group  
1614

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Hortobagyi, G.N. et al., "Paclitaxel-Containing Combination Chemotherapy for Metastatic Breast Cancer", Seminars in Oncology, Vol. 23, No. 1, Suppl. 1, pp. 53-57 (1996)
3AB	Baker, S.D., "Drug Interactions with the Taxanes", Pharmacotherapy, Vol. 17, No. 5, Pt. 2, pp. 126S-132S (1997)
3AC	Johnson, K. et al., "5-Fluorouracil interferes with taxol cytotoxicity on human solid tumor cells", Proceedings of the American Association for Cancer Research, Vol. 38, No. 2162, p. 323 (1997)
3AD	Johnson, K.R. et al., "5-Fluorouracil Interferes with Paclitaxel Cytotoxicity against Human Solid Tumor Cells", Clinical Cancer Research, Vol. 3, pp. 1739-1745 (1997)
3AE	Kano, Y. et al., "Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines <i>in vitro</i> ", British Journal of Cancer, Vol. 74, pp. 704-710 (1996)
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.